Regulation And Legal
Biocon's Pertuzumab Biosimilar Gets EMA CHMP Approval Recommendation
Biocon's subsidiary received EMA CHMP positive opinion for Pertuzumab biosimilar Pebrilzo® for HER2-positive breast cancer treatment.
This is the first monoclonal antibody biosimilar approved under EM
